List view / Grid view
18 June 2015 | By Victoria White
Lilly’s investigational medicine for the prevention of migraine, LY2951742, met the primary endpoint in a Phase 2b study in episodic migraine...
17 June 2015 | By
Lilly and SCRI have entered a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor...
Researchers have presented promising results from a clinical trial of the experimental drug baricitinib in people with diabetic kidney disease...
8 June 2015 | By Victoria White
Lilly’s basal insulin peglispro has consistently demonstrated superior HbA1c reduction in people with type 2 diabetes compared to insulin glargine in trials...
8 June 2015 | By Victoria White
Eli Lilly and Company has committed another 780,000 vials of insulin to the International Diabetes Federation's Life for a Child programme...
28 May 2015 | By Victoria White
Synjardy has been granted marketing authorisation by the European Commission for the treatment of adults with type 2 diabetes (T2D) in the European Union...
11 May 2015 | By Victoria White
Transition Therapeutics has exclusively licensed worldwide rights to a novel small molecule drug candidate, TT701, from Eli Lilly and Company...
6 May 2015 | By Victoria White
Lilly is set to establish a new drug delivery and device innovation centre in Cambridge, increasing its delivery and devise R&D space by almost 50%...
5 May 2015 | By Victoria White
Eli Lilly and Company has released two new reports that provide a comprehensive overview of the Company's corporate responsibility efforts...
29 April 2015 | By Victoria White
A recent survey has found that 52% of 275 ACS patients who were currently taking an oral antiplatelet have missed taking or changed the way they take it...
27 April 2015 | By Victoria White
The FDA has approved Cyramza in combination with FOLFIRI chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC)...
2 April 2015 | By Victoria White
OncoMed has entered into an agreement with Lilly. Demcizumab is being tested in combination with Alimta and carboplatin for the treatment of NSCLC...
30 March 2015 | By Victoria White
BI and Lilly announce they have received a positive opinion from CHMP, recommending empagliflozin/metformin hydrochloride for the treatment type 2 diabetes...
25 March 2015 | By Victoria White
Pfizer Inc. and Eli Lilly and Company have announced that they are preparing to resume the Phase 3 clinical programme for tanezumab...
23 March 2015 | By Victoria White
GLYXAMBI® tablets are now available by prescription in the US. GLYXAMBI offers improved glycemic control as an adjunct to diet and exercise...
